# Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

> **NCT03852823** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 192 (estimated)

## Conditions studied

- Advanced Solid Tumours
- Cervical Cancer
- Malignant Mesothelioma
- Lymphoma
- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** SG001

## Key facts

- **NCT ID:** NCT03852823
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-23
- **Primary completion:** 2022-09
- **Final completion:** 2023-03
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03852823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03852823, "Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03852823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*